Who are Fluoxetine + outpatient cognitive behavioral therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluoxetine-outpatient-cognitive-behavioral-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fluoxetine + outpatient cognitive behavioral therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluoxetine + outpatient cognitive behavioral therapy (Fluoxetine + outpatient cognitive behavioral therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI + psychotherapy combination. Area: Psychiatry / Mental Health.

marketed SSRI + psychotherapy combination Serotonin transporter (SERT) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Fluoxetine + outpatient cognitive behavioral therapy (Fluoxetine + outpatient cognitive behavioral therapy) — National Institute on Drug Abuse (NIDA). Fluoxetine increases serotonin availability in the brain while cognitive behavioral therapy teaches patients to identify and modify maladaptive thought patterns and behaviors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluoxetine + outpatient cognitive behavioral therapy TARGET	Fluoxetine + outpatient cognitive behavioral therapy	National Institute on Drug Abuse (NIDA)	marketed	SSRI + psychotherapy combination	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI + psychotherapy combination class)

National Institute on Drug Abuse (NIDA) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluoxetine + outpatient cognitive behavioral therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/fluoxetine-outpatient-cognitive-behavioral-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab